Has Susan Matesanz received payments from drug or device companies?

Yes. Drug and device makers reported $138,269 in general payments to Susan Matesanz across 71 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Susan Matesanz did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Susan Matesanz come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Susan Matesanz

Neurology with Special Qualifications in Child Neurology · Philadelphia, PANPI 1588009724

Payments from drug & device makers

What this record shows

This record is dominated by grants: $90,000 of the $138,269 with a category attached, or 65.1%. Biogen accounts for 65.7% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $90,095 and has fallen 78.8% since, to $19,074 in 2025. Among neurology with special qualifications in child neurology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$138,269in general payments, 2019–2025

Across 71 payments — averaging $1947.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Biogen$91K
Sarepta Therapeutics, Inc.$45K
Genentech, Inc.$1K
Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$529
Novartis$294
NS Pharma, Inc.$91

$619,137in research payments, 2019–2025

Across 112 payments — averaging $5528.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Sarepta Therapeutics, Inc.$386K
Pfizer$145K
Genentech, Inc.$85K
Novartis$3K

What the payments were for

Consulting fees$38,83828%
Grants$90,00065%
Travel & lodging$5,9134%
Food & beverage$3,5173%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Biogen	10	$90,859
Sarepta Therapeutics, Inc.	44	$45,135
Genentech, Inc.	7	$1,361
Novartis Gene Therapies, Inc. (fka Avexis, Inc.)	7	$529
Novartis	2	$294
NS Pharma, Inc.	1	$91

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$138,269 in reported general payments places this provider in the 95th percentile of 83 neurology with special qualifications in child neurology providers in Pennsylvania.

See all neurology with special qualifications in child neurology providers in Pennsylvania →

Other neurology with special qualifications in child neurology in Philadelphia

John BrandsemaPhiladelphia$526K
Elizabeth KichulaPhiladelphia$90K
Dennis DlugosPhiladelphia$88K
Alexandra KornbluhPhiladelphia$88K
Nicholas AbendPhiladelphia$56K
Sabrina YumPhiladelphia$33K
Eric MarshPhiladelphia$28K
Christina SzperkaPhiladelphia$18K
David LynchPhiladelphia$16K
Marissa DigiovinePhiladelphia$15K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →